Evidence map›Paper›PMID 35126932›Full record

ArticleJournal of healthcare engineering2022

FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer.

Lan Mu, Jian Zhang, Zhuo Wu, Jingxi Huang, Ying Cui

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lan MuDepartment of Otorhinolaryngology Head and Neck Surgery, First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.
Jian ZhangDepartment of Otorhinolaryngology Head and Neck Surgery, First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.
Zhuo WuCommunist Youth League Committee, First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.
Jingxi HuangDepartment of Gastroenterology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.
Ying CuiDepartment of Otorhinolaryngology Head and Neck Surgery, First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.ORCID 0000-0002-4792-2083
Jinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPrevious experiments have shown that growth factor receptors play important role in tumor proliferation, metastasis, and therapeutic effect of chemotherapeutic drugs. At the same time, forkhead box D1 (FOXD1) plays an important role in a variety of signal transmission, but its expression profile was known little about head and neck cancer. The purpose of this experiment was to explore the regulation of FOXD1 on the tumor progression of head and neck cancer and to explore the correlation of FOXD1 on the expression of growth factor receptors (EGFR).

methodsThe bioinformatics online database analyzed the expression of FOXD1 and EGFR in tumor tissues and nontumor tissues. Real-time quantitative PCR was used to detect the FOXD1 and EGFR expression in 45 tumor tissues and 15 nontumor tissues. The plasmid was used to construct FOXD1 overexpressing head and neck squamous cell cancer lines and observe the clonal formation and invasion of tumor cells under the intervention of EGFR-specific antibody-cetuximab.

resultsThe expression of FOXD1 and EGFR in tumor tissues was higher than that in nontumor tissues. The higher expression of FOXD1 and EGFR was not conducive to the prognosis of patients. The expression of FOXD1 and EGFR was positively correlated, and immunohistochemical analysis showed the high expression of FOXD1 and EGFR has close relation to the advanced stage of the tumor. In vitro cell experiments proved that overexpression of FOXD1 can partially offset the cloning ability of cetuximab on head and neck tumor cells.

conclusionFOXD1 has an important regulatory role in the progression of head and neck cancer, and its abnormally high expression was not conducive to the prognosis of cancer patients. FOXD1 can regulate the expression of growth factor receptors in head and neck cancer, which provides a new idea for the better use of tumor growth factor receptor-specific antibodies for collaborative therapy.

Indexed as

Gene Expression Regulation, NeoplasticHead and Neck NeoplasmsCell Line, TumorCetuximabEpithelial CellsErbB ReceptorsForkhead Transcription FactorsHumansReceptors, Growth FactorSquamous Cell Carcinoma of Head and NeckCetuximabEGFR protein, humanErbB ReceptorsForkhead Transcription FactorsFOXD1 protein, humanReceptors, Growth Factor

Identifiers

PMID35126932
PMCPMC8808214
OpenAlexW4210257529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.